TriangleTamoxifen (NCT05501704)
Tamoxifen trial for Male Breast Cancer (NCT05501704). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adult men with untreated stage I–III hormone-receptor-positive, HER2-negative breast cancer before surgery. Inflammatory breast cancer is excluded.
The idea: endocrine treatment reduces estrogen production or blocks its effects. A three-week randomized window compares tamoxifen, anastrozole, or anastrozole plus degarelix. The four-month phase tests tamoxifen or anastrozole plus degarelix; either regimen may include abemaciclib, a cell-cycle inhibitor. A biopsy after the window and surgery assess tumor changes.
This phase 2 study plans 60 patients. Jose Pablo Leone leads at Dana-Farber in Boston; nine US sites are recruiting.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.